3 completed, 2 suspended, 1 active not recruiting, 1 not yet recruiting. 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 3, Suspended 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Unknown 1 |
Follow Peritoneal Mesothelioma: new trials by email Literature Review of Peritoneal Mesothelioma trials Research Report on Peritoneal Mesothelioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First-line Treatment With Dual Immunotherapy Combined With Anti-angiogenesis for Unresectable Advanced Malignant Peritoneal Mesothelioma Sintilimab, Ipilimumab N01, Bevacizumab - Peritoneal Mesothelioma, First-line Therapy | Phase 2 | Not yet recruiting | Fudan University | 19 | 2026-10-30 | 2026-10-23 |
| IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers DOMVANALIMAB + ZIMBERELIMAB, DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4 - Peritoneal Mesothelioma, Gestational Trophoblastic Tumor | Phase 2 | Active not recruiting | Hospices Civils de Lyon | 27 | 2025-10-01 | 2026-06-25 |
| A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma Pemetrexed, Cisplatin, Carboplatin - Malignant Peritoneal Mesothelioma, Peritoneal Mesothelioma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 64 | 2023-09-21 | 2026-09-24 |
| A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers XmAb20717 - Microsatellite High Cancers, Peritoneal Mesothelioma | Phase 2 | Suspended | M.D. Anderson Cancer Center | 140 | 2022-08-05 | 2026-10-13 |
| A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma Nivolumab, Ipilimumab - Mesothelioma, Peritoneal Mesothelioma | Phase 2 | Completed | University of Chicago | 2 | 2021-12-01 | 2024-01-03 |
| Treatment of Malignant Peritoneal Mesothelioma (MESOTIP) PIPAC, Cisplatin, Pemetrexed - Peritoneal Mesothelioma, Peritoneal Carcinomatosis | Phase 2 | Suspended | Institut du Cancer de Montpellier - Val d'Aurelle | 66 | 2020-09-10 | 2026-02-09 |
| A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1) tremelimumab plus MEDI4736 - Pleural Mesothelioma, Peritoneal Mesothelioma | Phase 2 | Unknown | Italian Network for Tumor Biotherapy Foundation | 40 | 2015-10-01 | 2015-10-27 |
| HIPEC for Peritoneal Carcinomatosis HIPEC, Mitomycin C - Peritoneal Carcinomatosis, Colorectal Cancer | Phase 2 | Completed | Albert Einstein College of Medicine | 51 | 2011-11-01 | 2024-10-24 |
| Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy IMC-A12 - Pleural Mesothelioma, Peritoneal Mesothelioma | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2010-06-02 | 2018-04-10 |
Mesothelioma, Malignant (4) · Mesothelioma (2) · Peritoneal Neoplasms (2) · Appendiceal Neoplasms (1) · Carcinoid Tumor (1) · Carcinoma, Neuroendocrine (1) · Colorectal Neoplasms (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Gestational Trophoblastic Disease (1) · Hodgkin Disease (1) · Lung Neoplasms (1) · Pseudomyxoma Peritonei (1) · Small Cell Lung Carcinoma (1) · Stomach Neoplasms (1) · Thymoma (1)
Neoplasms (8) · Neoplasms by Site (8) · Neoplasms by Histologic Type (7) · Neoplasms, Glandular and Epithelial (7) · Thoracic Neoplasms (6) · Adenoma (5) · Lung Diseases (5) · Neoplasms, Mesothelial (5) · Respiratory Tract Diseases (5) · Respiratory Tract Neoplasms (5) · Lung Neoplasms (4) · Pleural Neoplasms (4) · Adenocarcinoma (3) · Carcinoma (3) · Mesothelioma (3)
Cisplatin (2) · Pemetrexed (2) · Bevacizumab (1) · Carboplatin (1) · Doxorubicin (1) · Hyperthermic Intraperitoneal Chemotherapy (1) · Ipilimumab (1) · Mitomycin (1) · Nivolumab (1) · cixutumumab (1) · durvalumab (1) · sintilimab (1) · tremelimumab (1) · zimberelimab (1)
Albert Einstein College of Medicine (1) · Fudan University (1) · Hospices Civils de Lyon (1) · Institut du Cancer de Montpellier - Val d'Aurelle (1) · Italian Network for Tumor Biotherapy Foundation (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · University of Chicago (1)
United States (5) · France (2) · China (1) · Italy (1)
Arvind Nageshwara Dasaru, MD (1) · Garrett Nash, MD (1) · John McAuliffe, M.D. (1) · Kiran Turaga, MD (1) · Luana Calabro', MD, PhD (1) · Raffit Hassan, M.D. (1)